US Hemp Round Table: NEW STUDY DEMONSTRATES CBD’S STRONG SAFETY PROFILE, AMPLIFIES CALLS FOR FDA REGULATION

US Hemp Round Table: NEW STUDY DEMONSTRATES CBD’S STRONG SAFETY PROFILE, AMPLIFIES CALLS FOR FDA REGULATION
CANNANNEW REPORT

Here’s their press release in full NEW STUDY DEMONSTRATES CBD’S STRONG SAFETY PROFILE, AMPLIFIES CALLS FOR FDA REGULATION Observational Data Collected On Long-term Consumption of Oral CBD Shows No Correlation To Safety Issues Raised by FDA A recently released, comprehensive safety study confirms prior research that orally-ingested cannabidiol (CBD) has a strong safety profile, providing data that addresses FDA’s specific safety concerns regarding CBD, with the results indicating that daily consumption across a range of typical retail products and serving sizes is not associated with elevated liver tests, low testosterone levels, or daytime drowsiness. The results renew calls from the hemp and CBD industries urging FDA to take steps to regulate CBD now, and calling on Congress to act if FDA continues to delay. The study was completed on March 22, 2022, and involved 1,061 participants, providing a 98% power rating on its results, which is statistically significant. Validcare contracted with 17 CBD companies and acted as the Contract Research Organization, which included gaining feedback from FDA on the protocol, conducting the study and publishing its results. The study abstract is available here. The first cohort of the study, which was peer-reviewed and published in Cannabis and Cannabinoid Medicine last year, observed 839 individuals taking CBD produced by twelve companies with the primary end point being liver function. The second cohort included an additional 222 individuals taking CBD produced by an additional five companies.  Their participation strengthened the statistical reliability of both the liver safety results and achieved statistical relevance for both sleep and testosterone results. The methods for both phases were the same. Adults 18-75 years of age across the United States, taking CBD orally for a minimum of 30 days, were recruited by seventeen individual CBD product companies in this decentralized, observational study and provided their standard CBD regimen. All product companies supplied a third-party certificate of analysis (COA) which was confirmed by a neutral third party to…

Excerpt only …
READ MORE BELOW
Source : US Hemp Round Table: NEW STUDY DEMONSTRATES CBD’S STRONG SAFETY PROFILE, AMPLIFIES CALLS FOR FDA REGULATION

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.